Large Jonathan M, Birchall Kristian, Bouloc Nathalie S, Merritt Andy T, Smiljanic-Hurley Ela, Tsagris Denise J, Wheldon Mary C, Ansell Keith H, Coombs Peter J, Kettleborough Catherine A, Whalley David, Stewart Lindsay B, Bowyer Paul W, Baker David A, Osborne Simon A
Centre for Therapeutics Discovery, LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
Centre for Therapeutics Discovery, LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126610. doi: 10.1016/j.bmcl.2019.08.014. Epub 2019 Aug 9.
Focussed studies on imidazopyridine inhibitors of Plasmodium falciparum cyclic GMP-dependent protein kinase (PfPKG) have significantly advanced the series towards desirable in vitro property space. LLE-based approaches towards combining improvements in cell potency, key physicochemical parameters and structural novelty are described, and a structure-based design hypothesis relating to substituent regiochemistry has directed efforts towards key examples with well-balanced potency, ADME and kinase selectivity profiles.
针对恶性疟原虫环磷酸鸟苷依赖性蛋白激酶(PfPKG)的咪唑并吡啶抑制剂的重点研究已使该系列在体外特性方面取得了显著进展。本文描述了基于配体效率(LLE)的方法,用于结合细胞活性、关键物理化学参数和结构新颖性方面的改进,并且一个与取代基区域化学相关的基于结构的设计假设已指导针对具有平衡活性、药物代谢动力学(ADME)和激酶选择性特征的关键实例展开研究。